gopubmed logo
 
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 31 Jul 2015.

Bruton agammaglobulinemia tyrosine kinase

Btk, XLA, Bruton's tyrosine kinase, Xid
The protein encoded by this gene plays a crucial role in B-cell development. Mutations in this gene cause X-linked agammaglobulinemia type 1, which is an immunodeficiency characterized by the failure to produce mature B lymphocytes, and associated with a failure of Ig heavy chain rearrangement. [provided by RefSeq, Nov 2008] (from NCBI)
Top mentioned proteins: BCR, CAN, Syk, Tec, V1a
Papers using Btk antibodies
Btk Is Required for an Efficient Response to Erythropoietin and for SCF-controlled Protection against TRAIL in Erythroid Progenitors
Supplier
von Lindern Marieke et al., In The Journal of Experimental Medicine, 1997
... Rabbit antisera recognizing the mouse EpoR, PLCγ1, Btk, c-Kit, and the antiphosphotyrosine mouse monoclonal antibody PY99 were obtained from Santa Cruz Biotechnology, Inc ...
Roles of Gβγ in membrane recruitment and activation of p110γ/p101 phosphoinositide 3-kinase γ
Supplier
Nürnberg Bernd et al., In The Journal of Cell Biology, 1997
... and BtkPH, restriction sites were introduced by PCR using the indicated primers, the Advantage™ II PCR enzyme system (CLONTECH Laboratories, Inc.) and the ...
The A and the extended V N-terminal regions of streptococcal protein I/IIf mediate the production of tumour necrosis factor alpha in the monocyte cell line THP-1.
Supplier
El Khoury Joseph, In PLoS ONE, 1997
... Anti-Btk mouse IgG monoclonal antibodies were from BD Transduction Laboratories (Le Pont de Claix, France) and anti-TNF-α mouse monoclonal antibodies were from Santa Cruz Biotechnology (Heidelberg, Germany) ...
Genomic organization and structure of Bruton agammaglobulinemia tyrosine kinase: localization of mutations associated with varied clinical presentations and course in X chromosome-linked agammaglobulinemia.
Supplier
Nukiwa Toshihiro et al., In Respiratory Research, 1993
... Briefly, mononuclear cells were surface stained with phycoerythrin-labeled anti-CD14 antibody, then fixed, permealized, incubated with anti-BTK monoclonal antibody 48-2H [5] or control IgG1 (Dako, Kyoto, Japan), and then ...
Papers on Btk
Ibrutinib: from bench side to clinical implications.
New
Scaglione et al., Milano, Italy. In Med Oncol, 30 Sep 2015
Thanks to the characterization and continuous discovery of the pathways driving B cell proliferation in consequence to BCR activation, it has been possible to develop a small molecule inhibitor specifically antagonizing the Bruton's tyrosine kinase (BTK), an enzyme located in an early strategic position within the whole pathway.
Genetic Interaction between Lyn, Ets1, and Btk in the Control of Antibody Levels.
New
Satterthwaite et al., Dallas, United States. In J Immunol, 24 Aug 2015
In the absence of these inhibitory components, Ets1 levels are reduced in B cells in a Btk-dependent manner.
Emerging therapeutic options for Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.
New
Gertz et al., Rochester, United States. In Expert Rev Anticancer Ther, 21 Aug 2015
Here, we review novel therapeutic agents in Waldenström macroglobulinemia/lymphoplasmacytic lymphoma, which have emerged in the past decade and discuss their comparative efficacy and safety, with emphasis on a Bruton's tyrosine kinase (BTK) inhibitor, which has been recently approved by the US FDA, specifically for Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.
Molecular Pathways: Targeting the CXCR4-CXCL12 Axis-Untapped Potential in the Tumor Microenvironment.
New
Scala, In Clin Cancer Res, 21 Aug 2015
The homeostatic microenvironment chemokine, CXCL12, binds the CXCR4 and CXCR7 receptors, activating divergent signals on multiple pathways such as ERK1/2, p38, SAPK/JNK, AKT, mTOR and the Bruton Tyrosine kinase (BTK).
Lectin binding to surface Ig variable regions provides a universal persistent activating signal for follicular lymphoma cells.
New
Stevenson et al., Southampton, United Kingdom. In Blood, 20 Aug 2015
Glycans added to sites are unusual in terminating at high mannoses.
[Ibrutinib: A new drug of B-cell malignancies].
Review
New
Thieblemont, Paris, France. In Bull Cancer, 30 Jun 2015
Ibrutinib (Imbruvica(®)) is a first-in-class, orally administered once-daily, that inhibits B-cell antigen receptor signaling downstream of Bruton's tyrosine kinase (BTK).
Rationale for targeting the pre-B cell receptor signaling pathway in acute lymphoblastic leukemia.
Review
New
Müschen, San Francisco, United States. In Blood, May 2015
Ibrutinib (BTK) and Idelalisib (PI3Kδ).
Ibrutinib in previously treated Waldenström's macroglobulinemia.
New
Impact
Advani et al., United States. In N Engl J Med, May 2015
MYD88(L265P) triggers tumor-cell growth through Bruton's tyrosine kinase, a target of ibrutinib.
B-cell receptor signaling in diffuse large B-cell lymphoma.
Review
New
Staudt et al., Bethesda, United States. In Semin Hematol, Apr 2015
Pharmacological inhibition with ibrutinib of Bruton's tyrosine kinase, a kinase that is required for BCR signaling to engage NF-κB, is selectively toxic for ABC DLBCL tumors; a finding that has now been translated to the clinic.
Multiple myeloma: Updates for pharmacists in the treatment of relapsed and refractory disease.
Review
New
Redic et al., Ann Arbor, United States. In J Oncol Pharm Pract, Mar 2015
New therapies currently in the drug development pipeline for relapsed and refractory disease include additional proteasome inhibitors (oprozomib, marizomib, ixazomib), histone deacetylase inhibitors (panobinostat, ricolinostat, quisinostat), monoclonal antibodies (daratumumab, elotuzumab, SAR650984), Bruton's tyrosine kinase inhibitors (ibrutinib), a selective inhibitor of nuclear export, and others.
Constitutive NF- κ B Activation Underlines Major Mechanism of Drug Resistance in Relapsed Refractory Diffuse Large B Cell Lymphoma.
Review
New
Turturro, Houston, United States. In Biomed Res Int, Dec 2014
Future efforts should aim at targeting the role of NF-κB resistance in clinical trials, where novel agents like lenalidomide and proteasome inhibitors with established activity in this perspective will be an important component in combination therapy, along with new monoclonal antibody, BTK-inhibitors, and other novel therapy agents.
Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.
New
Impact
O'Brien et al., Houston, United States. In Lancet Oncol, Sep 2014
BACKGROUND: Ibrutinib, an orally administered covalent inhibitor of Bruton's tyrosine kinase (BTK), is an effective treatment for relapsed chronic lymphocytic leukaemia (CLL).
Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
New
Impact
Oki et al., New York City, United States. In Lancet Oncol, Aug 2014
Pharmacodynamic data showed Bruton's tyrosine kinase was fully occupied (>90% occupancy) at the recommended phase 2 dose.
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
New
Impact
RESONATE Investigators et al., Aş Şanamayn, Syria. In N Engl J Med, Aug 2014
We evaluated the efficacy of ibrutinib, a covalent inhibitor of Bruton's tyrosine kinase, in patients at risk for a poor outcome.
Ibrutinib treatment of CLL: the cancer fights back.
New
Impact
Staudt et al., Bethesda, United States. In Cancer Cell, Aug 2014
Ibrutinib is a potent inhibitor of Bruton's tyrosine kinase (BTK).
Tyrosine kinase Btk is required for NK cell activation.
GeneRIF
Cao et al., Shanghai, China. In J Biol Chem, 2012
Data suggest a role of tyrosine kinase Btk in the regulation of immune cell unctions and innate inflammatory response.
Regulation of nucleocytoplasmic shuttling of Bruton's tyrosine kinase (Btk) through a novel SH3-dependent interaction with ankyrin repeat domain 54 (ANKRD54).
GeneRIF
Nore et al., Huddinge, Sweden. In Mol Cell Biol, 2012
mapped the interaction site to the C terminus of the Btk SH3 domain
Single-chain variable fragment intrabody impairs LPS-induced inflammatory responses by interfering with the interaction between the WASP N-terminal domain and Btk in macrophages.
GeneRIF
Kitani et al., Tsukuba, Japan. In Biochem Biophys Res Commun, 2012
These observations strongly suggest that the phosphorylation of WASP by Btk plays a pivotal role in transducing the LPS signaling pathway in macrophages.
Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice.
GeneRIF
Hendriks et al., Rotterdam, Netherlands. In Blood, 2012
Transgenic mice overexpressing Btk specifically in B cells spontaneously formed germinal centers and manifested increased plasma cell numbers, leading to antinuclear autoantibody production and systemic lupus erythematosus (SLE)-like autoimmune pathology.
Bruton's tyrosine kinase phosphorylates Toll-like receptor 3 to initiate antiviral response.
GeneRIF
Lam et al., Singapore, Singapore. In Proc Natl Acad Sci U S A, 2012
BTK plays a critical role in initiating TLR3 signaling.
share on facebooktweetadd +1mail to friends